Treatment of reactive arthritis with biological agents: a review

Zeng, Huiqiong; Luo, Baiwei; Zhang, Yue; Xie, Zhongyu; Ye, Zhizhong

doi:10.1042/bsr20191927

Cited by 25 publications

(18 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Disease-modifying anti-rheumatic drugs (DMARDs) such as sulfasalazine can also be used [ 5 ]. Recently, biologics have also been introduced in the management of ReA [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Reactive Arthritis After COVID-19 Infection

Jali¹

2020

Cureus

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is a novel virus that results in a variety of clinical manifestations. In this report, I describe an uncommon presentation of reactive arthritis (ReA) following COVID-19. I report the case of a 39-year-old woman who presented with arthritis in the small joints of the hands after recovery from COVID-19 infection. To my knowledge, only four cases involving such a presentation have been reported in the literature so far.

show abstract

“…Disease-modifying anti-rheumatic drugs (DMARDs) such as sulfasalazine can also be used [ 5 ]. Recently, biologics have also been introduced in the management of ReA [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Reactive Arthritis After COVID-19 Infection

Jali¹

2020

Cureus

View full text Add to dashboard Cite

show abstract

“…Der Einsatz biologischer Substanzen (im Wesentlichen TNF-Inhibitoren) ist nur in kleineren Fallserien bei definitiver ReA untersucht worden. Allerdings erfüllen Patienten bei chronischem Verlauf einer ReA mit einer Dauer von mehr als 6 Monaten und insbesondere bei positivem Nachweis von HLA-B27 die Kriterien der peripheren Spondyloarthritis, sodass sie innerhalb der Zulassung mit TNF-Inhibitoren behandelt werden können [18].…”

Section: Therapieunclassified

Reaktive Arthritis – eine vergessene Erkrankung?

Märker‐Hermann

2020

Dtsch Med Wochenschr

View full text Add to dashboard Cite

Was ist neu? Epidemiologie und Pathogenese Campylobacter jejuni/enteritidis ist in Westeuropa zu einem der häufigsten Erreger der ReA geworden. Auch nach mit Reisediarrhö assoziierten Escherischia-coli-Infektionen (DEC-Infektionen) können Arthralgien und milde ReA auftreten. HLA-B27 spielt eine Rolle bei der Erregerinvasion und -persistenz in Zellen der Mukosa und als antigenpräsentierendes Molekül. Neu sind Erkenntnisse, dass durch Auslösung einer Unfolded Protein Response (UPR) als Folge einer Fehlfaltung des HLA-B27-Moleküls eine proinflammatorische Stressantwort ausgelöst werden kann und dass enterobakterielle Infektionen diese Reaktion des angeborenen Immunsystems auslösen oder verstärken. Diagnostik Die Diagnostik beruht nicht auf einzelnen Parametern, sondern auf einer Kombination von klinischen, anamnestischen und serologischen bzw. PCR-basierten Faktoren. Therapie Antibiotika werden nur zur Therapie einer noch bestehenden Chlamydophilia-trachomatis-Infektion an der Eintrittspforte (urogenital) eingesetzt, nicht aber zur Therapie der posturethritischen oder postenteritischen ReA. Bei therapierefraktären chronischen Verläufen können Biologika (TNF-Inhibitoren) entsprechend ihrer Zulassung bei Spondyloarthritiden eingesetzt werden.

show abstract

“…Reactive arthritis (ReA), is a self-limiting disease; however, even 60% of patients may develop chronic arthritis [ 1 ]. The development of ReA is considered to be associated with past genitourinary or gastrointestinal infections [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

The Role of Yersinia enterocolitica O:3 Lipopolysaccharide in Collagen-Induced Arthritis

Kasperkiewicz

Swierzko

Przybyła

et al. 2020

Journal of Immunology Research

View full text Add to dashboard Cite

Yersinia enterocolitica O:3 is mentioned among the most common arthritogenic pathogens. Bacterial components (including lipopolysaccharide (LPS)) may persist in the joint after eradication of infection. Having an adjuvant activity, LPS may enhance production of anticollagen antibodies, involved in the pathogenesis of rheumatoid arthritis. Furthermore, its ability to activate complement contributes to the inflammation. The aim of this work was to investigate whether Yersinia LPS (coinjected with collagen) is associated with arthritis progression or other pathological effects and to elucidate the mechanism of this association. It was demonstrated that murine mannose-binding lectin C (MBL-C) recognizes the inner core heptoses of the Rd1 chemotype LPS of Yersinia. In addition, the Rd1 LPS activates the MBL-associated serine protease 1 (MASP-1) stronger than the S and Ra chemotype LPS and comparable to Klebsiella pneumoniae O:3 LPS. However, in contrast to the latter, Yersinia Rd1 LPS was associated neither with the adjuvancity nor with the enhancement of pathological changes in animal paws/impairment of motility. On the other hand, it seemed to be more hepatotoxic when compared with the other tested endotoxins, while the enlargement of inguinal lymph nodes and drop in hepatic MBL-C expression (at the mRNA level) were independent of LPS chemotype. Our data did not suggest no greater impact Y. enterocolitica O:3 on the development or severity of arthropathy related to anticollagen antibody-induced arthritis in mice, although its interaction with MBL-C and subsequent complement activation may contribute to some adverse effects.

show abstract

Treatment of reactive arthritis with biological agents: a review

Cited by 25 publications

References 54 publications

Reactive Arthritis After COVID-19 Infection

Reactive Arthritis After COVID-19 Infection

Reaktive Arthritis – eine vergessene Erkrankung?

The Role of Yersinia enterocolitica O:3 Lipopolysaccharide in Collagen-Induced Arthritis

Contact Info

Product

Resources

About